ASCO 2019 ANNUAL MEETING

ASCO 2019 ANNUAL MEETING

INTERVIEW WITH EVAN YU
Management of mCRPC using Sipuleucel-T

VIEW ALL mCRPC VIDEOS

ASCO 2019 ANNUAL MEETING

ASCO 2019 ANNUAL MEETING

INTERVIEW WITH JACOB BERCHUCK & MARY-ELLEN TAPLIN
Genetic Risk in Prostate Cancer

VIEW ALL PROSTATE CANCER VIDEOS

ASCO 2019 ANNUAL MEETING

ASCO 2019 ANNUAL MEETING

INTERVIEW WITH KARIM FIZAZI
ARAMIS Trial in Prostate Cancer: Impact of Darolutamide on Pain and Quality of Life

VIEW ALL nmCRPC VIDEOS

EAU 2019 ANNUAL MEETING

EAU 2019 ANNUAL MEETING

INTERVIEW WITH THOMAS POWLES
Immunotherapy in the Peri-Operative Setting for Bladder Cancer

VIEW ALL BLADDER CANCER VIDEOS

Videos
State-of-the-industry video lectures by leading urology experts
Featured Videos

#WCE2014 - Robot-assisted radical prostatectomy in high-risk prostate cancer - Interview

TAIPEI, TAIWAN (UroToday.com) - Introduction and Objectives: Interestingly, robot assisted radical prostatectomy (RARP) in the treatment of high-risk prostate cancer has not been well studied to date. We sought to evaluate all patients with high-risk prostate cancer undergoing RARP at our institution.

wceMethods: We performed a single-institution, single-surgeon review of 3,120 patients who underwent RARP from 2005 to 2012. Patients were identified who underwent RARP for high-risk disease as determined by D’Amico classification (Gleason 8–10, stage ≥T2c, and or PSA ≥20). Perioperative data was evaluated from a prospectively maintained RARP database. Treatment was considered a failure with PSA levels ≥0.2.

Results: In total, 319 patients were identified that met high-risk classification. The median age was 61. The median BMI was 28.29. Follow-up ranged from 11 to 98 months. 1-year biochemical recurrence free survival (1-RFS) was 81.8%. 2-year biochemical recurrence free survival (2-RFS) was 63.3%. Gleason score of 8–10 was the most common pre-operative high-risk identifier (64%). Positive surgical margins occurred in 29.8% of patients. Lymph node dissection was performed on 307 patients (96%). The 12 patients that did not receive a lymph node dissection had surgery prior to 2009. In total, 12 patients (3.9%) were found to have positive lymph node involvement.

Conclusions: We present our data for the treatment of high-risk prostate cancer with RARP. Consistent with recent, but limited data, RARP appears to be an effective initial treatment for high-risk prostate cancer. Further follow-up for these patients remains necessary to help better understand long-term outcomes following RARP for high-risk prostate cancer.

Source of Funding: None

 
Listen to an interview with Benjamin Katz, one of the authors of this study.

Presented by Andrew J. Lightfoot, Giovanni Greaves, Sue-Jean Yu, Elton Llukani, Benjamin F. Katz, Alice McGill, Kelly Monohan, Phillip Mucksavage, and David I. Lee at the 32nd World Congress of Endourology & SWL - September 3 - 7, 2014 - Taipei, Taiwan

University of Pennsylvania, Philadelphia, PA USA 

 

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Everyday Urology Volume 4 Issue 1

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe